JP2010506147A - 関節リウマチを有する患者のための疾患進行のリスク評価 - Google Patents
関節リウマチを有する患者のための疾患進行のリスク評価 Download PDFInfo
- Publication number
- JP2010506147A JP2010506147A JP2009529589A JP2009529589A JP2010506147A JP 2010506147 A JP2010506147 A JP 2010506147A JP 2009529589 A JP2009529589 A JP 2009529589A JP 2009529589 A JP2009529589 A JP 2009529589A JP 2010506147 A JP2010506147 A JP 2010506147A
- Authority
- JP
- Japan
- Prior art keywords
- markers
- patients
- score
- disease progression
- crp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010039073 rheumatoid arthritis Diseases 0.000 title claims abstract description 134
- 230000005750 disease progression Effects 0.000 title claims abstract description 81
- 206010061818 Disease progression Diseases 0.000 title claims abstract description 80
- 238000012502 risk assessment Methods 0.000 title description 2
- 239000003550 marker Substances 0.000 claims abstract description 84
- 108010074051 C-Reactive Protein Proteins 0.000 claims abstract description 77
- 102100032752 C-reactive protein Human genes 0.000 claims abstract description 77
- 102000004889 Interleukin-6 Human genes 0.000 claims abstract description 72
- 108090001005 Interleukin-6 Proteins 0.000 claims abstract description 72
- 229940100601 interleukin-6 Drugs 0.000 claims abstract description 71
- 238000000034 method Methods 0.000 claims abstract description 64
- 238000003498 protein array Methods 0.000 claims abstract description 7
- 210000000988 bone and bone Anatomy 0.000 claims description 28
- 210000000845 cartilage Anatomy 0.000 claims description 23
- 239000003435 antirheumatic agent Substances 0.000 claims description 13
- 238000005259 measurement Methods 0.000 claims description 12
- 239000003153 chemical reaction reagent Substances 0.000 claims description 11
- 230000002757 inflammatory effect Effects 0.000 claims description 10
- 230000005855 radiation Effects 0.000 claims description 10
- 108010024212 E-Selectin Proteins 0.000 claims description 9
- 239000002988 disease modifying antirheumatic drug Substances 0.000 claims description 9
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 8
- 102100030416 Stromelysin-1 Human genes 0.000 claims description 8
- 229920002674 hyaluronan Polymers 0.000 claims description 8
- 229960003160 hyaluronic acid Drugs 0.000 claims description 8
- 230000009870 specific binding Effects 0.000 claims description 8
- 210000001179 synovial fluid Anatomy 0.000 claims description 7
- 101000990915 Homo sapiens Stromelysin-1 Proteins 0.000 claims description 5
- 230000002068 genetic effect Effects 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 claims description 4
- 108010039343 HLA-DRB1 Chains Proteins 0.000 claims description 4
- 108700028369 Alleles Proteins 0.000 claims description 3
- 102000004067 Osteocalcin Human genes 0.000 claims description 3
- 108090000573 Osteocalcin Proteins 0.000 claims description 3
- 108010046732 HLA-DR4 Antigen Proteins 0.000 claims description 2
- 208000035474 group of disease Diseases 0.000 claims description 2
- 102000015689 E-Selectin Human genes 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 28
- 238000011282 treatment Methods 0.000 abstract description 18
- 238000000338 in vitro Methods 0.000 abstract description 6
- 238000011156 evaluation Methods 0.000 abstract description 4
- 230000002250 progressing effect Effects 0.000 abstract description 2
- 230000035945 sensitivity Effects 0.000 description 28
- 239000000523 sample Substances 0.000 description 23
- 230000003628 erosive effect Effects 0.000 description 22
- 206010003246 arthritis Diseases 0.000 description 21
- 230000006870 function Effects 0.000 description 17
- 230000004054 inflammatory process Effects 0.000 description 17
- 210000001503 joint Anatomy 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- 206010061218 Inflammation Diseases 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 241000219061 Rheum Species 0.000 description 12
- 239000000090 biomarker Substances 0.000 description 12
- 210000002683 foot Anatomy 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 102000008186 Collagen Human genes 0.000 description 11
- 108010035532 Collagen Proteins 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 230000008859 change Effects 0.000 description 11
- 229920001436 collagen Polymers 0.000 description 11
- 230000006378 damage Effects 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 230000000875 corresponding effect Effects 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 102100032442 Protein S100-A8 Human genes 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 238000003745 diagnosis Methods 0.000 description 9
- 210000000707 wrist Anatomy 0.000 description 9
- 102100023471 E-selectin Human genes 0.000 description 8
- 238000004422 calculation algorithm Methods 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 7
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 6
- 102000000589 Interleukin-1 Human genes 0.000 description 6
- 108010002352 Interleukin-1 Proteins 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
- 108010061103 cyclic citrullinated peptide Proteins 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 201000004595 synovitis Diseases 0.000 description 6
- 102000012422 Collagen Type I Human genes 0.000 description 5
- 108010022452 Collagen Type I Proteins 0.000 description 5
- 102100032420 Protein S100-A9 Human genes 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000003018 immunoassay Methods 0.000 description 5
- 238000007477 logistic regression Methods 0.000 description 5
- 238000007619 statistical method Methods 0.000 description 5
- 102000000503 Collagen Type II Human genes 0.000 description 4
- 108010041390 Collagen Type II Proteins 0.000 description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- 206010023203 Joint destruction Diseases 0.000 description 4
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 4
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 4
- 102100029812 Protein S100-A12 Human genes 0.000 description 4
- 102000013674 S-100 Human genes 0.000 description 4
- 108700021018 S100 Proteins 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 230000001186 cumulative effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- 210000001255 hallux Anatomy 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 208000037821 progressive disease Diseases 0.000 description 4
- 230000000750 progressive effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 210000001258 synovial membrane Anatomy 0.000 description 4
- 238000012549 training Methods 0.000 description 4
- 238000007473 univariate analysis Methods 0.000 description 4
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 3
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 3
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 108010028750 Integrin-Binding Sialoprotein Proteins 0.000 description 3
- 102000016921 Integrin-Binding Sialoprotein Human genes 0.000 description 3
- 206010023232 Joint swelling Diseases 0.000 description 3
- 102000005741 Metalloproteases Human genes 0.000 description 3
- 108010006035 Metalloproteases Proteins 0.000 description 3
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 3
- 101710108790 Stromelysin-1 Proteins 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000011382 collagen catabolic process Effects 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 230000009266 disease activity Effects 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 210000004247 hand Anatomy 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000002427 irreversible effect Effects 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000007637 random forest analysis Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 2
- 206010051728 Bone erosion Diseases 0.000 description 2
- 102100026622 Cartilage intermediate layer protein 1 Human genes 0.000 description 2
- 101710176668 Cartilage oligomeric matrix protein Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- ZAHDXEIQWWLQQL-IHRRRGAJSA-N Deoxypyridinoline Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(O)=C(C[C@H](N)C([O-])=O)C(CC[C@H](N)C(O)=O)=C1 ZAHDXEIQWWLQQL-IHRRRGAJSA-N 0.000 description 2
- 108060003393 Granulin Proteins 0.000 description 2
- 101000913767 Homo sapiens Cartilage intermediate layer protein 1 Proteins 0.000 description 2
- 108010072582 Matrilin Proteins Proteins 0.000 description 2
- 102000055008 Matrilin Proteins Human genes 0.000 description 2
- 101710195116 Melanoma-derived growth regulatory protein Proteins 0.000 description 2
- 102100022185 Melanoma-derived growth regulatory protein Human genes 0.000 description 2
- 101000783348 Naja atra Cytotoxin 1 Proteins 0.000 description 2
- 101000761722 Naja kaouthia Cytotoxin 1 Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- LCYXYLLJXMAEMT-SAXRGWBVSA-N Pyridinoline Chemical compound OC(=O)[C@@H](N)CCC1=C[N+](C[C@H](O)CC[C@H](N)C([O-])=O)=CC(O)=C1C[C@H](N)C(O)=O LCYXYLLJXMAEMT-SAXRGWBVSA-N 0.000 description 2
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000003150 biochemical marker Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 230000008416 bone turnover Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 210000003797 carpal joint Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000007635 classification algorithm Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000002790 cross-validation Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 229940125721 immunosuppressive agent Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000000811 metacarpophalangeal joint Anatomy 0.000 description 2
- 210000000878 metatarsophalangeal joint Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000000491 multivariate analysis Methods 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000003813 thumb Anatomy 0.000 description 2
- 210000003857 wrist joint Anatomy 0.000 description 2
- ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 description 1
- 108010067219 Aggrecans Proteins 0.000 description 1
- 102000016284 Aggrecans Human genes 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102000055007 Cartilage Oligomeric Matrix Human genes 0.000 description 1
- 102100027473 Cartilage oligomeric matrix protein Human genes 0.000 description 1
- 102100024484 Codanin-1 Human genes 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- RCPOVANIIKXVTB-YPPRVYOWSA-N Galactosylhydroxylysine Chemical compound NCCCC[C@@H](C(O)=O)N(O)C1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O RCPOVANIIKXVTB-YPPRVYOWSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 101000980888 Homo sapiens Codanin-1 Proteins 0.000 description 1
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 1
- 101000741967 Homo sapiens Presequence protease, mitochondrial Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 101150101999 IL6 gene Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 102100040448 Leukocyte cell-derived chemotaxin 1 Human genes 0.000 description 1
- 101710125682 Leukocyte cell-derived chemotaxin 1 Proteins 0.000 description 1
- 238000007476 Maximum Likelihood Methods 0.000 description 1
- 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 241001111421 Pannus Species 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102100038632 Presequence protease, mitochondrial Human genes 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 108700028909 Serum Amyloid A Proteins 0.000 description 1
- 102000054727 Serum Amyloid A Human genes 0.000 description 1
- 101710084578 Short neurotoxin 1 Proteins 0.000 description 1
- 108010032838 Sialoglycoproteins Proteins 0.000 description 1
- 102000007365 Sialoglycoproteins Human genes 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000011256 aggressive treatment Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000003811 finger Anatomy 0.000 description 1
- 210000000610 foot bone Anatomy 0.000 description 1
- 210000003108 foot joint Anatomy 0.000 description 1
- -1 for example Proteins 0.000 description 1
- 238000002986 genetic algorithm method Methods 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000002411 hand bone Anatomy 0.000 description 1
- 210000002478 hand joint Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000008407 joint function Effects 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 210000005067 joint tissue Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000012886 linear function Methods 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 238000010801 machine learning Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012067 mathematical method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000010339 medical test Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108010034596 procollagen Type III-N-terminal peptide Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000010666 regulation of catalytic activity Effects 0.000 description 1
- 230000029892 regulation of protein phosphorylation Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 238000012066 statistical methodology Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012706 support-vector machine Methods 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 230000008409 synovial inflammation Effects 0.000 description 1
- 210000005222 synovial tissue Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000001692 type a synoviocyte Anatomy 0.000 description 1
- 210000002192 type b synovial cell Anatomy 0.000 description 1
- 210000000623 ulna Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4737—C-reactive protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5412—IL-6
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Rehabilitation Therapy (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06020645 | 2006-09-29 | ||
| EP06021887 | 2006-10-19 | ||
| PCT/EP2007/008313 WO2008037420A1 (en) | 2006-09-29 | 2007-09-25 | Assessing the risk of disease progression for a patient with rheumatoid arthritis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010506147A true JP2010506147A (ja) | 2010-02-25 |
| JP2010506147A5 JP2010506147A5 (enExample) | 2010-07-15 |
Family
ID=38859738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009529589A Pending JP2010506147A (ja) | 2006-09-29 | 2007-09-25 | 関節リウマチを有する患者のための疾患進行のリスク評価 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8058013B2 (enExample) |
| EP (1) | EP2074428B1 (enExample) |
| JP (1) | JP2010506147A (enExample) |
| CA (1) | CA2663730A1 (enExample) |
| ES (1) | ES2545688T3 (enExample) |
| WO (1) | WO2008037420A1 (enExample) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012103238A (ja) * | 2010-10-14 | 2012-05-31 | Nagasaki Univ | 免疫複合体の網羅的解析方法および新規関節リウマチバイオマーカー |
| JP2013508687A (ja) * | 2009-10-15 | 2013-03-07 | クレッシェンド バイオサイエンス インコーポレイテッド | 炎症性疾患活動性を測定およびモニタリングするためのバイオマーカーおよび方法 |
| US10718765B2 (en) | 2014-04-02 | 2020-07-21 | Crescendo Bioscience, Inc. | Biomarkers and methods for measuring and monitoring juvenile idiopathic arthritis activity |
| US10983120B2 (en) | 2015-09-29 | 2021-04-20 | Crescendo Bioscience | Methods for assessing response to inflammatory disease therapy withdrawal |
| US11493512B2 (en) | 2014-06-10 | 2022-11-08 | Laboratory Corporation Of America Holdings | Biomarkers and methods for measuring and monitoring axial spondyloarthritis activity |
| US11656227B2 (en) | 2015-09-29 | 2023-05-23 | Crescendo Bioscience | Biomarkers and methods for assessing psoriatic arthritis disease activity |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010038104A1 (en) * | 2008-10-03 | 2010-04-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combination of cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event. |
| US20130246097A1 (en) * | 2010-03-17 | 2013-09-19 | Howard M. Kenney | Medical Information Systems and Medical Data Processing Methods |
| JP5786020B2 (ja) * | 2010-04-16 | 2015-09-30 | アボットジャパン株式会社 | 関節リウマチを診断する方法および試薬 |
| WO2012012183A2 (en) * | 2010-06-30 | 2012-01-26 | New York University | Quantifying local inflammatory activity and its use to predict disease progression and tailor treatments |
| WO2012061821A1 (en) * | 2010-11-06 | 2012-05-10 | Crescendo Bioscience | Biomarkers for predicting progressive joint damage |
| CN105229470B (zh) * | 2013-03-15 | 2018-11-27 | 艾克斯肯诊断股份有限公司 | 用于治疗和诊断系统性红斑狼疮的方法 |
| JP2015061592A (ja) * | 2013-08-21 | 2015-04-02 | コニカミノルタ株式会社 | 超音波診断装置、超音波画像処理方法およびコンピュータ読み取り可能な非一時的な記録媒体 |
| GB201603571D0 (en) * | 2016-03-01 | 2016-04-13 | Univ Warwick | Markers for skeletal disorders |
| WO2021087116A1 (en) * | 2019-10-30 | 2021-05-06 | Cd Diagnostics, Inc. | Biomarkers of early osteoarthritis |
| CN114089632B (zh) * | 2021-11-15 | 2023-08-18 | 陕西师范大学 | 基于模糊逻辑的风湿免疫疾病特征识别方法及系统 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005085859A1 (en) * | 2004-02-27 | 2005-09-15 | Roche Diagnostics Gmbh | Method of assessing rheumatoid arthritis by measuring rheumatoid factor and interleukin-6 |
| WO2006098401A1 (ja) * | 2005-03-16 | 2006-09-21 | The University Of Tokushima | 関節リウマチ罹患リスクの測定方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9105893D0 (en) * | 1991-03-20 | 1991-05-08 | Orion Yhtymae Oy | Bone resorption assay based on a peptide liberated during collagen degradation |
| US5888510A (en) * | 1993-07-21 | 1999-03-30 | Chugai Seiyaku Kabushiki Kaisha | Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component |
| ES2154739T3 (es) * | 1994-10-17 | 2001-04-16 | Osteometer Biotech As | Estimacion del modelo de fragmentacion del colageno en fluidos corporales y el diagnostico de trastornos asociados con el metabolismo del colageno. |
| FR2752842B1 (fr) | 1996-08-30 | 1998-11-06 | Biomerieux Sa | Antigenes derives des filaggrines et leur utilisation pour le diagnostic de la polyarthrite rhumatoide |
| NL1004539C2 (nl) | 1996-11-15 | 1998-05-20 | Stichting Tech Wetenschapp | Peptide afgeleid van een door auto-antilichamen van patiënten met reumatoïde artritis herkend antigeen, antilichaam daartegen en werkwijze voor het detecteren van auto-immuunantilichamen. |
| AU2155899A (en) | 1997-11-28 | 1999-06-16 | Innogenetics N.V. | Synthetic peptides containing citrulline recognized by rheumatoid arthritis sera as tools for diagnosis and treatment |
| FR2773157B1 (fr) | 1997-12-30 | 2001-10-05 | Bio Merieux | Epitopes peptidiques reconnus par des auto-anticorps antifilaggrine presents dans le serum des patients atteints de polyarthrite rhumatoide |
| CN1284942A (zh) * | 1998-01-09 | 2001-02-21 | 辉瑞大药厂 | 基质金属蛋白酶抑制剂 |
| WO2001046222A2 (en) | 1999-12-21 | 2001-06-28 | Innogenetics N.V. | Peptides designed for the diagnosis and treatment of rheumatoid arthritis |
| NL1019540C2 (nl) | 2001-12-11 | 2003-07-01 | Stichting Tech Wetenschapp | Werkwijze voor het detecteren van auto-antilichamen van patienten die lijden aan reumatoïde artritis, peptide en assaykit. |
| US20060063162A1 (en) * | 2004-09-23 | 2006-03-23 | Deng David X | Biological marker for inflammation |
| EP1926747A1 (en) * | 2005-08-12 | 2008-06-04 | Schering Corporation | Mcp1 fusions |
-
2007
- 2007-09-25 ES ES07818398.5T patent/ES2545688T3/es active Active
- 2007-09-25 WO PCT/EP2007/008313 patent/WO2008037420A1/en not_active Ceased
- 2007-09-25 EP EP07818398.5A patent/EP2074428B1/en not_active Not-in-force
- 2007-09-25 CA CA002663730A patent/CA2663730A1/en not_active Abandoned
- 2007-09-25 JP JP2009529589A patent/JP2010506147A/ja active Pending
-
2009
- 2009-03-27 US US12/412,840 patent/US8058013B2/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005085859A1 (en) * | 2004-02-27 | 2005-09-15 | Roche Diagnostics Gmbh | Method of assessing rheumatoid arthritis by measuring rheumatoid factor and interleukin-6 |
| WO2006098401A1 (ja) * | 2005-03-16 | 2006-09-21 | The University Of Tokushima | 関節リウマチ罹患リスクの測定方法 |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013508687A (ja) * | 2009-10-15 | 2013-03-07 | クレッシェンド バイオサイエンス インコーポレイテッド | 炎症性疾患活動性を測定およびモニタリングするためのバイオマーカーおよび方法 |
| US9200324B2 (en) | 2009-10-15 | 2015-12-01 | Crescendo Bioscience | Biomarkers and methods for measuring and monitoring inflammatory disease activity |
| US11300575B2 (en) | 2009-10-15 | 2022-04-12 | Laboratory Corporation Of America Holdings | Biomarkers and methods for measuring and monitoring inflammatory disease activity |
| JP2012103238A (ja) * | 2010-10-14 | 2012-05-31 | Nagasaki Univ | 免疫複合体の網羅的解析方法および新規関節リウマチバイオマーカー |
| US10718765B2 (en) | 2014-04-02 | 2020-07-21 | Crescendo Bioscience, Inc. | Biomarkers and methods for measuring and monitoring juvenile idiopathic arthritis activity |
| US11493512B2 (en) | 2014-06-10 | 2022-11-08 | Laboratory Corporation Of America Holdings | Biomarkers and methods for measuring and monitoring axial spondyloarthritis activity |
| US10983120B2 (en) | 2015-09-29 | 2021-04-20 | Crescendo Bioscience | Methods for assessing response to inflammatory disease therapy withdrawal |
| US11656227B2 (en) | 2015-09-29 | 2023-05-23 | Crescendo Bioscience | Biomarkers and methods for assessing psoriatic arthritis disease activity |
| US12385912B2 (en) | 2015-09-29 | 2025-08-12 | Laboratory Corporation Of America Holdings | Methods of treatment of arthritic disorders |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2074428B1 (en) | 2015-07-01 |
| CA2663730A1 (en) | 2008-04-03 |
| WO2008037420A1 (en) | 2008-04-03 |
| EP2074428A1 (en) | 2009-07-01 |
| ES2545688T3 (es) | 2015-09-15 |
| US8058013B2 (en) | 2011-11-15 |
| US20090270272A1 (en) | 2009-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8058013B2 (en) | Assessing risk of disease progression in rheumatoid arthritis patients | |
| Visser | Early diagnosis of rheumatoid arthritis | |
| Hurnakova et al. | Serum calprotectin (S100A8/9): an independent predictor of ultrasound synovitis in patients with rheumatoid arthritis | |
| US8062907B2 (en) | Method to assess the severity of rheumatoid arthritis by measuring anti-CCP and serum amyloid A | |
| JP4495168B2 (ja) | 抗ｃｃｐおよびインターロイキン６の測定による慢性関節リウマチの評価方法 | |
| CN101283278A (zh) | 在类风湿性关节炎的诊断中的抗ccp和抗核抗体 | |
| Fex et al. | Tissue-derived macromolecules and markers of inflammation in serum in early rheumatoid arthritis: relationship to development of joint destruction in hands and feet. | |
| CN101523218B (zh) | 评估类风湿性关节炎患者疾病进展的风险 | |
| JP4610605B2 (ja) | リウマチ因子およびインターロイキン６の測定による慢性関節リウマチの評価方法 | |
| CN104105967B (zh) | 生腱蛋白c及其在类风湿关节炎的用途 | |
| HK1136628B (en) | Assessing the risk of disease progression for a patient with rheumatoid arthritis | |
| HK1136628A (en) | Assessing the risk of disease progression for a patient with rheumatoid arthritis | |
| El Kosaier et al. | Serum amyloid a level and musculoskeletal ultrasound in assessment of disease activity in rheumatoid arthritis patients | |
| Yasin et al. | Extensive study of CCN4, VCAM-1, MMP-3, and GM-CSF as reliable markers for disease activity in rheumatoid arthritis | |
| WO2012098256A1 (en) | Anti-cd146 auto-antibodies and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100527 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100527 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110810 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20110810 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111110 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120508 |